

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : G01N 33/68, C12Q 1/00 C07K 15/00	A1	(11) International Publication Number: WO 90/0712 (43) International Publication Date: 28 June 1990 (28.06.90)
(21) International Application Number: PCT/US89/05560 (22) International Filing Date: 13 December 1989 (13.12.89) (30) Priority data: 284,212 14 December 1988 (14.12.88) US (60) Parent Application or Grant (63) Related by Continuation US 284,212 (CIP) Filed on 14 December 1988 (14.12.88) (71) Applicant (for all designated States except US): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 300 Lakeside Drive, 22nd Floor, Oakland, CA 94612 (US).		(72) Inventors; and (75) Inventors/Applicants (for US only) : ROBERTS, James, I [US/US]; 321 Corta Madera Avenue, Mill Valley, CA 94941 (US). TAYLOR, Robert, N. [US/US]; 118 Gravenhill Way, San Francisco, CA 94127 (US). (74) Agent: WEBER, Kenneth, A.; Townsend & Townsend One Market Plaza, 2000 Steuart Tower, San Francisco CA 94105 (US). (81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), DK, ES (European patent), FR (European patent), G (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent), US. Published <i>With international search report.</i>

(54) Title: DIAGNOSTIC ASSAY FOR THE DETECTION OF PREECLAMPSIA

(57) Abstract

This invention relates to the diagnosis of preeclampsia using an assay to measure a mitogenic factor in blood. Preeclampsia is a serious problem in pregnant women. It is an idiopathic life threatening hypertensive condition. The condition of preeclamptic women can often deteriorate to a point where serious injury will occur to either the mother, child or both. Preeclampsia is a leading cause of death both maternal and infant.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauretania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

DIAGNOSTIC ASSAY FOR THE DETECTION OF PREECLAMPSIA

BACKGROUND OF THE INVENTION

5 Field of the Invention

This invention relates to the diagnosis of preeclampsia using an assay to measure a mitogenic factor in blood. Preeclampsia is a serious problem in pregnant women. It is an idiopathic life threatening hypertensive
10 condition. The condition of preeclamptic women can often deteriorate to a point where serious injury will occur to either the mother, child or both. Preeclampsia is a leading cause of death both maternal and infant.

Information Disclosure

15 Preeclampsia occurs in 7-10% of pregnancies and is responsible for significant maternal and fetal morbidity (Roberts, J.M., Pregnancy-related hypertension. In: Creasy, R.K.; Resnick R., eds., Maternal-Fetal Medicine-Principles and Practice, Philadelphia: W.B.
20 Saunders, 1984, 703-752). Despite decades of interest and research, the pathogenesis of this disease is still poorly understood. Recent evidence, however, suggests that endothelial cell injury may play an important role in the preeclamptic syndrome. The histopathological
25 findings of endothelial lesions in renal and umbilical vessels obtained from preeclamptic patients have been recognized (Spargo, B.H.; McCartney, C.P.; Winemiller, R., Glomerular capillary endotheliosis in toxemia of pregnancy. AMA Arch. Pathol., 1959, 68:593-497; Dadak
30 C., Ulrich W., Sinzinger H. Morphological changes in the umbilical arteries of babies born to preeclamptic mothers: an ultrastructural study. Placenta 1984, 5:419-426). Lately, several reports have documented biochemical abnormalities in serum from preeclamptic
35 patients which support the concept that endothelial cell

perturbation and sublethal injury of these cells may contribute to the pathogenesis of preeclampsia. Most of these studies have been indirect, showing elevated levels of endothelial cell products in serum (e.g., fibronectin (Stubbs, T.M.; Lazarchick, J.; Horger, E.O., III, Plasma fibronectin levels in preeclampsia: a possible biochemical marker for vascular endothelial damage. Am. J. Obstet. Gynecol., 1984, 150:885-887), factor VIII antigen (Redman, C.W.G.; Beilin, L.J.; Stirrat, G.M., et al., Factor VIII consumption in preeclampsia. Lancet 1977, II:1249-1252), or platelet and coagulation abnormalities (Roberts, J.M., Pregnancy-related hypertension, In: Creasy, R.K.; Resnick, R., eds., Maternal-Fetal Medicine-Principles and Practice. Philadelphia: W.B. Saunders, 1984, 703-752). We have recently demonstrated directly that serum from preeclamptic women injures endothelial cells in vitro (Rodgers, G.M.; Taylor, R.N.; Roberts, J.M., Preeclampsia is associated with a serum factor cytotoxic to human endothelial cells, Am. J. Obstet. Gynecol, 159:908-914, 1988).

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1

Mitogenic dose-response of cultured fibroblasts exposed to serum from normal and preeclamptic patients. Quiescent fibroblasts were incubated with paired pre- and postpartum sera from normal and preeclamptic patients as described in Materials and Methods. Incorporation of ^3H -thymidine into fibroblast DNA increased in a dose-dependent, logarithmic fashion. Shown are mitogenic activities of prepartum (open box) and postpartum (closed box) sera from normal (A) and preeclamptic (B) patients. There was a significant left-shift of the curve for prepartum as compared to postpartum preeclamptic serum but not in paired sera from normal pregnancy ($P < 0.01$).

Figure 2

Mitogenic activity of sera from normal and preeclamptic patients. (A) Direct comparison of prepartum sera from preeclamptic and normal patients
5 diluted to a final concentration of 2% demonstrated a 46% increase in mitogenic activity in preeclamptic sera as compared to normal ($P < 0.01$). (B) Serum collected at 24-48 hours postpartum revealed no difference between the two groups ($P > 0.6$).

10 Figure 3

No indirect effect of magnesium sulfate ($MgSO_4$) treatment on the mitogenic activity of sera from preeclamptic patients. Two groups of preeclamptic patients were compared. One group ($n = 4$) had received
15 intravenous $MgSO_4$ prior to the prepartum blood sample collection. In the other group ($n = 4$), blood specimens were collected before treatment with $MgSO_4$. The percent mitogenic stimulation (pre-/post- X 100) values were not different ($P > 0.6$).

20 SUMMARY OF THE INVENTION

This invention relates to the discovery of a mitogenic factor present in the blood of preeclamptic women. This factor is a proteineous compound of about 160 kDa. This factor permits the prediction, detection
25 and diagnosis of preeclampsia. It is capable of stimulating fibroblast mitosis. However, this factor is heat and acid labile in sera when the sera is measured for mitogenic activity after acidification or heating.

Also described herein is a diagnostic assay for
30 the prediction and detection of preeclampsia comprising the in vivo detection of mitogenic activity in blood from pregnant women. The assay can be direct or indirect. This assay is particularly disclosed wherein the mitogenic activity is detected using either fibroblast or
35 smooth muscle cells. More particularly, the assay can

comprise the detection of mitogenic activity by monitoring the uptake of radiolabelled thymidine by cells directly stimulated to begin mitosis.

It is preferred that the blood being assayed be
5 fractionated into serum or plasma samples.

There is also disclosed herein an in vitro method for detecting preeclampsia comprising measuring mitogenic activity of blood from women with preeclampsia. More specifically this method can involve the direct assay of
10 mitogenic activity of fibroblast or smooth muscle cells. The method preferably uses human cells. Most specifically disclosed is a method for detecting radiolabelled thymidine uptake by cells activated by the sera or plasma of preeclamptic women.

15 A kit for assaying for mitogenic activity in blood from preeclamptic women is also described herein. The kit will comprise instructions, negative and positive controls, means for direct or indirect measurement of mitogenic activity such as cell culturing means and means
20 for quantifying or measuring the mitogenic activity of the blood.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

This invention involves the discovery that mitotic stimulating compounds are present in preeclamptic
25 women. The sera of these women differ significantly in mitogenic activity in standard assays for the detection of mitosis. The presence of such activity forms the basis of the diagnostic assays disclosed herein.

Characteristics of the Mitogenic Factor

30 The mitogenic factor is a proteinaceous compound of approximately 160 kDa. This factor has a demonstrated sensitivity to protease. In addition, sera containing this factor loses its mitogenic activity below a pH of 3.0 (as tested after reneutralization of the sera). The
35 factor has a negative charge at neutral pH. The

component is also heat sensitive. When sera is heated, the factor is mitogenically inactivated after 1 hr. at 60°C. Purification of this factor can be achieved using standard protein purification techniques which include
5 sizing gels, selective precipitation by salt, ion exchange columns and the like.

Sample Collection

The described assays preferably use a serum or plasma sample. Arterial or venous blood can be used. It
10 is preferred that the samples be taken from a vein. The blood should be centrifuged within 10 hrs and the plasma or serum fraction collected. The assays can be performed on fresh or frozen samples. The mitogenic activity is stable at -70 degrees C for up to 4 months.

15 Samples may be taken between 3 months and before termination of the pregnancy. It is an advantage of this invention that mitotic activity precedes the hypertensive condition.

In Vitro Assays for Mitogenic Activity

20 A number of different assays have been described for measuring mitogenic activity. A review of these assays can be found in Keski-Oja, J., et al., Transforming Growth Factors and Control of Neoplastic Cell Growth, J. Cell. Bioch., 33:95-107, 1987. Typically
25 these assays measure some function accompanying the transition of cells from the resting state into the replication state. Such functions include:

1. The incorporation of tritiated thymidine into cellular DNA.

30 2. The stimulation of DNA synthesis, measured by total DNA concentrations using the chromogenic dye diphenylamine.

3. Cellular proliferation measured by increases in cell number as measured using a hemocytometer or
35 coulter cell counter.

4. Stimulation of anchorage-independent growth, as measured by cell colony formation in soft agar.

It is particularly convenient to measure thymidine uptake which directly reflects DNA synthesis.

5 Mammalian cells for which cell culturing parameters have been described are of primary use herein. Typically these cells are susceptible to mitogenic stimulation and include murine and human cells. It is preferred that the cells used in the described assays be
10 derived from human tissues. Most preferably fibroblast or smooth muscle cells, in our tests human endothelial cells were not sensitive to the mitogenic compound described herein.

A kit for the direct measuring of mitogenic
15 activity would include instructions, negative controls from normal blood, positive controls derived from patients with preeclampsia and cells sensitive to mitogenic stimulation. Culturing means for growth of cells would include, media and sterile culture flasks.
20 A labeled nutrient or other means for measuring mitosis may also be included.

Indirect Measurement

In addition to the direct measurement of mitogenic activity, it is possible to assay for the
25 mitogenic activity indirectly. Indirect mitogenic activity involves the measuring of the specific blood factor associated or responsible for activating mitogenesis in the in vitro assays. Methods for identifying and quantifying the mitogenic factor include
30 HPLC, electrophoretic separations and immunoassays. Immunoassays are preferred and a multitude of standard immunoassays are available for indirect measurement. These include competitive immunoassays such as ELISA, IRMA (immunoradiometric assay) and RIA. The indirect
35 method of detection has the advantage of being quicker, less expensive and readily incorporated into routine

diagnostic use.

Any of the above assays can be designed to function as an assay in the disclosed invention.

Prediction of Preeclampsia

5 The preeclamptic condition is predicted by a statistically significant elevation in the levels of mitogenic factor as early as the second trimester of pregnancy. This elevation can be detected months before the onset of the clinical manifestations of preeclampsia.

10 A prospectively collected group of women were followed during their pregnancy. Serial plasma samples were collected, diluted to 2%, and analyzed for mitogenic activity using the human foreskin fibroblast cell assay described below. Comparisons of thymidine uptake by the
15 cells were made for four preeclamptic and six normal control primigravidae. Comparisons were made using the Mann-Whitney test with the results of each patient's plasma mitogenic activity normalized to her immediate postpartum sample. For analysis, the normalized
20 predelivery values for each patient were reduced to averages, overall and separately for each trimester. The overall averaged data indicated that women predestined to meet strict American College of Obstetrics and Gynecology (ACOG) criteria for the diagnosis of preeclampsia had
25 significantly elevated pre- to post-delivery ratios of plasma mitogenic (growth) factor activity throughout pregnancy, as compared to prospectively sampled normal primigravidae (1.7 ± 0.2 vs. 0.8 ± 0.1 , mean \pm SEM, $P < 0.005$). Similar statistical analyses of averaged
30 mitogenic activity for each trimester appeared to distinguish women destined to develop preeclampsia from their normal peers as early as the second trimester (2.0 ± 0.4 vs. 0.8 ± 0.1 , $P < 0.005$).

35 The following examples illustrate the functionality of the invention described herein. The examples are not to be construed as a limitation on the

claims. It being further understood that non-critical variations in procedures by those of skill are possible.

EXAMPLES

Serum Samples

- 5 Serum samples are obtained from pregnant patients with and without preeclampsia. Venous blood samples were collected in most cases.

Cell Culture

- 10 Human foreskin fibroblasts (passages 10 through 20) were obtained from the U.C.S.F. Cell Culture Facility and maintained in culture using a growth medium of Dulbecco's Modified Eagle's Medium (DMEM) with 4.5 g/liter glucose supplemented with 10% fetal calf serum, penicillin/streptomycin (100 U/ml) and fungizone (500
15 ng/ml), at 37°C in a humidified atmosphere and 5% CO₂. Cells were plated at a density of 5 x 10⁴ cells per well in 24-well Falcon dishes, grown to confluence and then maintained in a quiescent state with serum-free medium for 48 to 72 hours prior to exposure to patient serum.
20 Serum-free medium was prepared using DMEM but supplemented with 20 mM HEPES, insulin (1 µg/ml), transferrin (0.5 µg/ml), and bovine serum albumin (500 µg/ml, Sigma), in place of fetal calf serum.

Thymidine Incorporation Assay

- 25 Mitogenic activity of serum was determined by measuring the incorporation of ³H-thymidine into nascent DNA by fibroblasts as described by DiCorleto and Bowne-Pope (DiCorleto, P.E.; Bowen-Pope, D.F., Cultured endothelial cells produce a platelet-derived growth
30 factor-like protein, Proc. Natl. Acad. Sci. U.S.A., 1983, 80:1919-1923). Briefly, aliquots of patients' sera were added to triplicate wells containing confluent quiescent fibroblast cultures to yield a final serum

concentration of 2% (final protein concentration \pm SD = 1.5 ± 0.4 mg/ml). After 20 hours of incubation, ^3H -thymidine (0.5 $\mu\text{Ci}/\text{well}$, 15.7 Ci/mmol, New England Nuclear) were added to each well and labeling was carried out for 4 hours. Thymidine incorporation into 10% trichloroacetic acid insoluble nucleic acid was determined by scintillation counting.

Mitogenic activity was expressed either as total cpm ^3H -thymidine incorporated per well of confluent fibroblasts or as percent mitogenic stimulation. The latter was defined as (cpm incorporated predelivery)/(cpm incorporated postdelivery) \times 100. All values were expressed as the mean \pm SE of triplicate assays.

Protein Determination

Protein concentrations of the serum samples were quantified by the method of Bradford (Bradford, M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding, Anal. Biochem. 1976, 72:248-254).

Statistics

Evaluations of statistical significance were performed using analysis of variance and Students' t-test (two-tailed analysis) where appropriate. Tests with $P < 0.01$ were considered to reflect significant differences.

Patients

Consecutive patients were recruited from admissions to the Obstetrical Service of the Medical Center at the University of California, San Francisco (UCSF). All had term, singleton gestations and the diagnosis of preeclampsia was made based on the following criteria: no prior history of hypertension or renal disease; a rise in blood pressure of at least 30 mm Hg systolic or 15 mm Hg diastolic, or if these were not

known a blood pressure of at least 140 mm Hg systolic or 90 mm Hg diastolic (manifested on two readings at least 6 hours apart); and proteinuria of $\geq 1+$ (~ 30 mg/dl) urine protein on a catheterized specimen. Normal, contr 1
5 patients had no history of hypertension; were normotensive throughout gestation; and had no proteinuria (Table I). Edema was not used to define preeclampsia for inclusion in this study. Mean arterial pressure (MAP) was calculated from the average of blood pressure
10 readings taken from admission to delivery (MAP = diastolic + [systolic - diastolic]/3).

Serum Samples

Venous blood samples were collected in early labor and again at 24-48 hours postpartum in accordance
15 with a protocol approved by the UCSF Committee on Human Research. The serum fraction was separated by centrifugation and stored frozen for up to four months at -70° C prior to assay.

Results

20 A. Comparison of mitogenic activities of pre- and postpartum serum.

Initial studies were performed to determine the mitogenic effect of increasing concentrations of serum on human foreskin fibroblasts in culture. There was a dose
25 dependent increase in ^3H -thymidine incorporation from 0.04 to 4 mg/ml serum protein. No difference in mitogenic potency was seen in paired sera from normal parturients (Figure 1A). However, matched pre- and postpartum specimens from preeclamptic patients showed a
30 significant left-shift of the dose response curve in the prepartum specimens as compared to postdelivery samples ($P < 0.01$ for serum concentrations greater than 1 mg/ml protein, Figure 1B). These data defined the range of serum protein concentrations that allowed differences to
35 be detected in the subsequent cross-sectional analyses.

Experiments comparing a larger number of patients were done at a fixed, final serum concentration of 2% (final serum protein concentration \pm SD = $1.5 \pm -/0.4$ mg/ml). Paired pre- and postpartum serum samples of 13 preeclamptic and 10 control parturients were compared and normalized using the postpartum value for each patient. Percent mitogenic stimulation (pre-/post- \times 100) was significantly increased in paired preeclamptic sera (mean \pm SE = $107 \pm 6\%$; $P < 0.01$). The coefficient of variation of the thymidine incorporation assay was 12%. No changes in serum-induced mitogenic activity were observed even after multiple freeze-thaw cycles.

Mitogenic activity in prepartum serum.

In order to determine whether the elevated mitogenic stimulation seen in paired preeclamptic sera was due to greater prepartum activity or decreased postpartum activity, or both, comparisons of antepartum and postpartum sera were performed. Direct comparison of prepartum sera from 15 preeclamptic and 14 normal patients showed a 46% increase in the mean level of thymidine incorporation of the preeclamptic specimens over the amount in normal specimens ($P < 0.01$, Figure 2a). However, in a separate experiment, direct comparison of postpartum sera collected 24-48 hours after delivery revealed no significant difference in mitogenic activity between normal and preeclamptic patients ($n = 12$, Figure 2B).

Effect of magnesium sulfate on mitogenic activity.

We addressed the possibility that increased mitogenic activity in preeclamptic vs. normal sera might be secondary to magnesium sulfate (MgSO_4) therapy administered uniformly to preeclamptic patients at our institution. The direct addition of MgSO_4 at concentrations of 2 and 6 mg/dl (levels comparable to serum levels in treated patients) to control predelivery

serum, did not affect the incorporation of ^3H -thymidine by these samples ($P > 0.6$, Table II). To determine whether differences in mitogenic activity between patient groups could be attributed to an indirect effect of MgSO_4 treatment, paired pre- and postpartum sera from two groups of preeclamptic patients were compared. One group (I, $n = 4$) had received intravenous MgSO_4 prior to the prepartum blood sample collection. In the other group (II, $n = 4$), specimens were collected before treatment with MgSO_4 . The percent mitogenic stimulation values were (Group I: mean \pm SE = $135 \pm 9.5\%$; Group II: mean \pm SE = $141 \pm 5.9\%$, $P > 0.6$; Figure 3).

13

TABLE I

PATIENT DATA

5		NORMAL	PREECLAMPTIC
		(n = 14)	(n = 15)
	Gestational Age (weeks)	39.5 ± 1.5	38.5 ± 1.9
10	Mean Arterial Pressure (mm Hg)	84 ± 3.1	107 ± 10.7*
	Urine Protein (mg/dl)	0 - trace	30 - 300
	Uric Acid (mg/dl)	ND}	5.6 ± 1.8
	Platelets (K/ml)	ND§	261 ± 65

15

values are expressed as mean ± SD

* P<0.01

ND = not determined

} normal value at 37-40 weeks = 4.4 ± 0.8 mg/dl

20

§ normal value (non-pregnant) = 150-400 K/ml

TABLE II

NO DIRECT EFFECT OF MgSO_4
ON MITOGENIC ACTIVITY OF SERUM

5	MgSO_4 added (mg/dl)			
		0	2	6
	^3H -thymidine incorporated/well	42,723	42,540	41,257
	(cpm \pm SE)	$\pm 3,046$	$\pm 3,360$	$\pm 2,438$

10 Legend

Quiescent human fibroblasts were incubated for 24 hours in the presence of 2% serum from a normal, prepartum woman, supplemented with 0, 2, or 6 mg/dl (final concentration in the serum) magnesium sulfate (MgSO_4). ^3H -thymidine uptake was determined in triplicate as described in Materials and Methods. Analysis of variance revealed no differences between the three treatments ($P > 0.6$).

WHAT IS CLAIMED IS:

1. A diagnostic assay for the detection and prediction of preeclampsia comprising (a) collecting blood samples from pregnant women; and (b) detecting
5 mitogenic activity of the blood.

2. An assay of claim 1 wherein the detecting of mitogenic activity is achieved by measuring mitosis in animal cells selected from the group consisting of fibroblast and smooth muscle cells.

10 3. An assay of claim 2 wherein serum or plasma samples are prepared from the blood and wherein mitogenic activity is detected by exposing the animal cells to the serum or plasma samples.

15 4. A diagnostic assay of claim 2 wherein the detecting step (b) comprises measuring radiolabeled thymidine uptake by the animal cells exposed to the samples.

20 5. A method for the diagnosis of preeclampsia comprising (a) collecting blood from a pregnant woman; and (b) detecting a mitogenic factor in the blood wherein said factor has a molecular weight of about 160 kDA, a proteinaceous component, is protease sensitive, having a negative charge at neutral pH capable of stimulating fibroblast mitosis and exhibiting, when present in sera,
25 acid and heat lability with respect to its mitogenic activity.

30 6. A method of claim 5 wherein detecting of mitogenic activity further comprises the measuring of mitogenic activity in animal cells selected from the group consisting of fibroblast and smooth muscle cells exposed to the blood.

7. A method of claim 6 wherein the mitogenic activity is measured by detecting radiolabeled thymidine uptake by cells activated by the sera.

5 8. A method of claim 6 wherein serum or plasma samples are prepared from the blood and wherein mitogenic activity is detected by exposing the animal cells to the serum or plasma samples.

10 9. A kit for the diagnosis of preeclampsia comprising: a container containing human cells, said cells responsive to mitogenic activity in blood from women with preeclampsia, a container containing radiolabeled thymidine and a container containing the mitogenic factor derived from the blood of preeclamptic women.

15 10. A mitogenic factor of blood for diagnosing and predicting preeclampsia, said factor having a molecular weight of about 160 kDa, having a proteinaceous component, a negative charge at neutral pH being protease sensitive, capable of stimulating fibroblast mitosis and
20 exhibiting, when present in sera, acid and heat lability with respect to its mitogenic activity.

1/2





FIG. 1.

2/2





FIG. 2.




FIG. 3.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US89/05560

I. CLASSIFICATION F SUBJECT MATTER (if several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC 5 GOIN 33/68; C12Q 1/00; C07K 15/00

US Cl. 435/29, 34, 35, 810; 436/63, 65, 510, 519, 808; 422/61; 530/350

II. FIELDS SEARCHED

Classification System

Minimum Documentation Searched 7

Classification Symbols

US Cl.

435/29, 34, 35, 810
436/63, 65, 510, 519, 808
422/61; 530/350

Documentation Searched other than Minimum Documentation
to the extent that such Documents are included in the Fields Searched *

III. DOCUMENTS CONSIDERED TO BE RELEVANT *

Category *	Citation of Document, 11 with indication, where appropriate, of the relevant passages 12	Relevant to Claim No. 13
X, P	American Journal of Obstetrics and Gynecology, Volume 159, issued 1988 December, T.J. Musci et al, "Mitogenic Activity is Increased in the Sera of Preclampsia Women Before Delivery," pages 1446-1451. See abstract page 1446	1-10
A	La Ricerca Clin. Lab., Volume 11, issued 1981, L. Cagnoli et al, "Lymphocyte Hyporesponsiveness During Edema, Proteinuria and Hypertension (EPH) Gestosis," pages 229-238	
A	British Journal of Experimental Pathology, Volume 55, issued 1974, J.M. Gaugas et al, "Complement Fixing Antibody Against Solubilized Placental Microsomal Fraction in Pre-Eclampsia Sera," pages 570-574	
A	British Journal of Obstetrics and Gynecology, Volume 84, issued 1977 December, C.W.G. Redman et al, "Plasma Urate and Serum Deoxycytidylate Deaminase Measurements of the Early Diagnosis of Pre-Eclampsia," pages 904-908	

* Special categories of cited documents: 10

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

Date of Mailing of this International Search Report

02 MARCH 1990

05 APR 1990

International Searching Authority

Signature of Authorized Officer

ISA/US

Christine M. Nicker
CHRISTINE M. NICKER